Abstract:The phosphatidylinositol 3-kinase (PI3K) signaling pathway is critical in modulating platelet functions. In the present study, we evaluated the effect of S14161, a recently identified pan-class I PI3K inhibitor, on platelet activation and thrombus formation. Results showed that S14161 inhibited human platelet aggregation induced by collagen, thrombin, U46619, and ADP in a dose-dependent manner. Flow cytometric studies showed that S14161 inhibited convulxin-or thrombin-induced P-selectin expression and fibrinogen binding of single platelet. S14161 also inhibited platelet spreading on fibrinogen and clot retraction, processes mediated by outside-in signaling. Using a microfluidic chamber we demonstrated that S14161 decreased platelet adhesion on collagen-coated surface by about 80%. Western blot showed that S14161 inhibited phosphorylation of Akt at both Ser473 and Thr308 sites, and GSK3 beta at Ser9 in response to collagen, thrombin, or U46619. Comparable studies showed that S14161 has a higher potential bioavailability than LY294002, a prototypical inhibitor of pan-class I PI3K. Finally, the effects of S14161 on thrombus formation in vivo were measured using a ferric chloride-induced carotid artery injury model in mice. The intraperitoneal injection of S14161 (2 mg/kg) to male C57BL/6 mice significantly extended the first occlusion time (5.05 +/- 0.99 min, n = 9) compared to the vehicle controls (3.72 +/- 0.95 min, n = 8) (P<0.05), but did not prolong the bleeding time (P>0.05). Taken together, our data showed that S14161 inhibits platelet activation and thrombus formation without significant bleeding tendency and toxicity, and considering its potential higher bioavailability, it may be developed as a novel therapeutic agent for the prevention of thrombotic disorders.

Developments in Inhibiting Platelet Aggregation Based on Different Design Strategies

Review ontheEffect of Tea on PlateletActivation

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic

New Medicine for Antithrombotic Treatment of Atrial Fibrillation—Who Can Dominate in the Future

Inhibition of platelet activation and aggregation

Advances of Antiplatelet Therapies

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

The effects of ginsenosides on platelet aggregation and vascular intima in the treatment of cardiovascular diseases: From molecular mechanisms to clinical applications

Mechanisms of thrombosis and research progress on targeted antithrombotic drugs

Bioactive Peptides and Proteins As Alternative Antiplatelet Drugs

Research Progress of Platelet Glycoprotein Ⅱb/Ⅲa Acceptor Antagonist

Procoagulant Platelets: Generation, Characteristics, and Therapeutic Target.

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Current status and progress of percutaneous coronary intervention-related platelet P2Y12 receptor blockers

Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis

Anti-Platelet Peptides Targeting αIIbβ3 Outside-In Signaling Pathway

Inhibition of Platelet Adhesion to Exposed Subendothelial Collagen by Steric Hindrance with Blocking Peptide Nanoparticles

Platelets in Hemostasis and Thrombosis: Novel Mechanisms of Fibrinogen-Independent Platelet Aggregation and Fibronectinmediated Protein Wave of Hemostasis

Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs

Therapeutic effects and molecular mechanisms of natural products in thrombosis

Regulation of Platelet Activation and Coagulation: Current Concepts, Novel Targets, and Therapies